Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.
Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] is Merck’s bivalent combination vaccine that offers protection against infections caused by Hib and all known subtypes of HBV. Comvax contains the antigenic components used in Merck’s PedvaxHIB and Recombivax HB vaccines. Upon receiving FDA approval for use in infants six weeks to 15 months of age in 1996, Comvax became the first combination vaccine in the US to protect its recipients against HBV infection. Currently, Comvax is only marketed in the US, as its EU market authorization, under the name Procomvax, was not renewed in 2009.
Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Comvax including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Comvax for the US from 2012 to 2022.
Sales information covered for the US
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Comvax performance
Obtain sales forecast for Comvax from 2012-2022 in the US.
Sales of Comvax in the Prophylactic HBV Vaccines Market
The combined sales of Comvax were estimated at $37.3 million in 2012. By 2022, we project Comvax sales to fall to $2.7 million, with a negative Compound Annual Growth Rate (CAGR) of 23.2% over the course of the decade. These estimates cover the sales in the eight countries included in this report: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada.
Key factors contributing to sales of Comvax will include:
A bivalent vaccine, Comvax protects against both HBV and Hib in one shot, reducing the infant shot burden.
Marketed in the US since 1996, Comvax enjoys a good reputation for safety and effectiveness among physicians.
Despite these drivers, the major barriers affecting the sales of Comvax will include:
Due to the Hib component of the vaccine, Comvax may not be administered to infants <6 weeks of age, which restricts its label compared with GSK’s Engerix-B.
Comvax is only marketed in the US, limiting its global sales growth.